studies

breast cancer - HER2-positive, trastuzumab deruxtecan vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsDESTINY Breast03, 2022 0.55 [0.36; 0.85] 0.55[0.36; 0.85]DESTINY Breast03, 202210%NAnot evaluable progression or deaths (PFS)detailed resultsDESTINY Breast03, 2022 0.28 [0.22; 0.36] 0.28[0.22; 0.36]DESTINY Breast03, 202210%NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-06-15 15:19 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 1233

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons